Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

AIMS/INTRODUCTION: Sodium–glucose cotransporter 2 inhibitors, as well as thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative studies have been reported. Dapagliflozin has shown non‐inferiority compared with pioglitazone for glycemic control, and superiority reg...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Diabetes Investig
Auteurs principaux: Cho, Kyu Yong, Nakamura, Akinobu, Omori, Kazuno, Takase, Takahiro, Miya, Aika, Yamamoto, Kohei, Nomoto, Hiroshi, Kameda, Hiraku, Taneda, Shinji, Kurihara, Yoshio, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2020
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264405/
https://ncbi.nlm.nih.gov/pubmed/33131199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13457
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires